Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium
valproate when given to patients with advanced solid tumors. Then to explore the antitumor
effects of the neratinib and sodium valproate combination in advanced solid tumors with
attention to RAS-mutated tumors, EGFR-altered GBM, and ocular melanoma, as part of the phase
2 expansion cohort.